308 related articles for article (PubMed ID: 37576433)
1. A multidisciplinary approach to treating a unique case of recurrent metastatic thymic carcinoma: case report.
Wang C; Erick Elkowitz D; Esposito MJ; Shah RD; Tannous H; Barilla-Labarca ML; Seetharamu N
Ther Adv Rare Dis; 2023; 4():26330040231190661. PubMed ID: 37576433
[TBL] [Abstract][Full Text] [Related]
2. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.
Finazzi T; Rordorf T; Ikenberg K; Huber GF; Guckenberger M; Garcia Schueler HI
BMC Cancer; 2018 Apr; 18(1):395. PubMed ID: 29625593
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab Plus Chemotherapy in Metastatic Thymic Carcinoma: A Case Report.
Thomas QD; Basse C; Luporsi M; Girard N
Front Oncol; 2021; 11():814544. PubMed ID: 35127529
[TBL] [Abstract][Full Text] [Related]
5. Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report.
Hines J; Daily E; Pham AK; Shea CR; Nadeem U; Husain AN; Stadler WM; Reid P
J Med Case Rep; 2021 Mar; 15(1):124. PubMed ID: 33736690
[TBL] [Abstract][Full Text] [Related]
6. Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression.
Isshiki T; Isobe K; Tochigi N; Sunakawa M; Nakamura Y; Shibuya K; Sakamoto S; Takai Y; Homma S
Case Rep Oncol; 2018; 11(3):688-692. PubMed ID: 30483099
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report.
Siciliano MA; Dastoli S; d'Apolito M; Staropoli N; Tassone P; Tagliaferri P; Barbieri V
Front Oncol; 2020; 10():579445. PubMed ID: 33163407
[TBL] [Abstract][Full Text] [Related]
8. Robust and durable response to first-line treatment of pembrolizumab combined with chemotherapy in two patients with metastatic thymic squamous cell carcinoma: Case report.
Chen C; Sun P; Long J
Front Immunol; 2022; 13():941092. PubMed ID: 35983052
[TBL] [Abstract][Full Text] [Related]
9. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
10. Stage III-IV thymic squamous cell carcinoma in complete pathological remission achieved with thymic cancer resection after immunotherapy combined with chemotherapeutic conversion therapy: a report of two cases from real-world data.
Li D; Minervini F; Planas G; Okuda K; Ozeki N; Zou Y
Gland Surg; 2024 Jan; 13(1):117-127. PubMed ID: 38323230
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab as a novel therapeutic option for patients with refractory thymic epithelial tumor: A case report.
Wong-Chong J; Bernadach M; Ginzac A; Veyssière H; Durando X
World J Clin Cases; 2021 Feb; 9(5):1139-1147. PubMed ID: 33644178
[TBL] [Abstract][Full Text] [Related]
12. Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer.
Baroz AR; Mambetsariev I; Fricke J; Pharaon R; Tan T; Kidambi T; Sandhu KS; Koczywas M; Salgia R
Cureus; 2021 Jul; 13(7):e16266. PubMed ID: 34377604
[TBL] [Abstract][Full Text] [Related]
13. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
Beck TN; Kudinov AE; Dulaimi E; Boumber Y
BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
[TBL] [Abstract][Full Text] [Related]
14. Conversion surgery for microsatellite instability-high gastric cancer with a complete pathological response to pembrolizumab: a case report.
Hidaka Y; Arigami T; Osako Y; Desaki R; Hamanoue M; Takao S; Kirishima M; Ohtsuka T
World J Surg Oncol; 2022 Jun; 20(1):193. PubMed ID: 35689267
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of advanced thymic carcinoma with lymph node and pleural metastases: A case report.
Yamamoto Y; Kodama K; Maniwa T; Kishima H
Mol Clin Oncol; 2016 Nov; 5(5):550-552. PubMed ID: 27900082
[TBL] [Abstract][Full Text] [Related]
16. Case Report: Durable Complete Response After Combined Immunotherapy Following Resection of Primary Tumor in a Gallbladder Cancer Patient With Distant Metastatic Lymph Nodes of Favorable Immune-Microenvironment.
Yi B; Zhao Z; Dong H; Yuan L; Wu Y; Xu Y; Jiang X; Sun C; Wu D; Xiao Y
Front Immunol; 2022; 13():820566. PubMed ID: 35242133
[TBL] [Abstract][Full Text] [Related]
17. A patient with advanced lung squamous cell carcinoma who failed to benefit from albumin bound paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus pembrolizumab: a case report.
Zhang F; Xu Y; Guo S; Li S; Ma K; Wang J; Wei S
Ann Palliat Med; 2022 Sep; 11(9):3020-3027. PubMed ID: 36217630
[TBL] [Abstract][Full Text] [Related]
18. Case Report: Two Cases of Chemotherapy Refractory Metastatic Penile Squamous Cell Carcinoma With Extreme Durable Response to Pembrolizumab.
Chahoud J; Skelton WP; Spiess PE; Walko C; Dhillon J; Gage KL; Johnstone PAS; Jain RK
Front Oncol; 2020; 10():615298. PubMed ID: 33425770
[TBL] [Abstract][Full Text] [Related]
19. Immune-Therapy-Related Toxicity Events and Dramatic Remission After a Single Dose of Pembrolizumab Treatment in Metastatic Thymoma: A Case Report.
Shen L; Chen H; Wei Q
Front Immunol; 2021; 12():621858. PubMed ID: 33936037
[TBL] [Abstract][Full Text] [Related]
20. Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer.
Shukla NA; Althouse S; Meyer Z; Hanna N; Durm G
Clin Lung Cancer; 2021 Jul; 22(4):274-281. PubMed ID: 33610454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
